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Abstract
Background: Efficacy studies indicate anti-depressive effects of at least some second generation antipsychotics
(SGAs). The Bergen Psychosis Project (BPP) is a 24-month, pragmatic, industry-independent, randomized, head-to-
head comparison of olanzapine, quetiapine, risperidone and ziprasidone in patients acutely admitted with
psychosis. The aim of the study is to investigate whether differential anti-depressive effectiveness exists among
SGAs in a clinically relevant sample of patients acutely admitted with psychosis.
Methods: Adult patients acutely admitted to an emergency ward for psychosis were randomized to olanzapine,
quetiapine, risperidone or ziprasidone and followed for up to 2 years. Participants were assessed repeatedly using
the Positive and Negative Syndrome Scale - Depression factor (PANSS-D) and the Calgary Depression Scale for
Schizophrenia (CDSS).
Results: A total of 226 patients were included. A significant time-effect showing a steady decline in depressive
symptoms in all medication groups was demonstrated. There were no substantial differences among the SGAs in
reducing the PANSS-D score or the CDSS sum score. Separate analyses of groups with CDSS sum scores > 6 or ≤6,
respectively, reflecting degree of depressive morbidity, revealed essentially identical results to the primary analyses.
There was a high correlation between the PANSS-D and the CDSS sum score (r = 0.77; p < 0.01).
Conclusions: There was no substantial difference in anti-depressive effectiveness among olanzapine, quetiapine,
risperidone or ziprasidone in this clinically relevant sample of patients acutely admitted to hospital for symptoms of
psychosis. Based on our findings we can make no recommendations concerning choice of any particular SGA for
targeting symptoms of depression in a patient acutely admitted with psychosis.
Trial Registration: ClinicalTrials.gov ID; URL: http://www.clinicaltrials.gov/: NCT00932529
Background
Depressive symptoms are common in psychotic disor-
ders, illustrated by point prevalence figures in patients
with schizophrenia between 7-75% [1,2]. These figures
vary due to different sub-populations and different defini-
tions of depression. The modal rate has been estimated at
25% [2]. The identification of depression in this patient
group is challenging for several reasons, including the
overlap between depressive symptoms and the negative
symptoms of psychosis and depressive features being
common in the prodromal phase of schizophrenia [1].
Nevertheless, depression should be diagnosed and prop-
erly treated as it is associated with increased distress,
poorer functional performance, a poorer quality of life,
increased rates of relapse and increased mortality related
to suicide [3-6].
Anti-depressive properties have been indicated for
several second generation antipsychotics (SGAs) [7-11].
Different hypotheses exist regarding the mechanisms by
which the SGAs mediate their anti-depressive effects,
including antagonism of serotonergic 5HT2 receptors;
agonism of 5HT1 receptors; antagonism of adrenergic a2
receptors and inhibition of trans-membrane monoamine
transporters [12-14]. The evidence for efficacy is stron-
gest in bipolar depression in which some SGAs have
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any medium, provided the original work is properly cited.become agents of first choice [10]. Pragmatic studies of
anti-depressive effectiveness of SGAs in more heteroge-
neous, naturalistic samples with psychosis are scarce
[15,16]. Short-term studies do, however, indicate anti-
depressive effects of several SGAs in non-affective
psychosis [17]. Olanzapine was superior to haloperidol in
reducing depressive symptoms in a 6-week study [18]. In
patients with treatment refractory schizophrenia, quetia-
pine was found to be superior to haloperidol in reducing
depressive symptoms during the 8-week follow-up [19].
Both studies were sponsored by the pharmaceutical
industry. Some studies have indicated a marked superior-
ity of clozapine in reducing the risk of suicide and
depressive symptoms compared to the other antipsycho-
tics [20]. In some recent studies quetiapine has demon-
strated anti-depressive properties in both clinically
depressed and non-depressed populations [9,21,22].
There are indications that studies sponsored by the phar-
maceutical industry selectively report data in favour of
the sponsored drug [23].
Clearly, more long-term studies are needed on the
highly prevalent occurrence of depressive symptoms in
psychosis. In particular, comparative effectiveness trials of
first-line SGAs funded independently of the pharmaceuti-
cal industry are called for in order to provide clinically
relevant evidence on whether or not differential anti-
depressive effectiveness exists among the drugs. We have
previously reported the superior effectiveness of quetiapine
on several outcomes other than depression [24]. The over-
all depression outcome was reported only briefly. Depres-
sion and depressive symptoms are, however, the main foci
in the present study with a larger sample.
The primary aim of the present pragmatic, randomized
study is to investigate whether differential anti-depressive
effectiveness exists among olanzapine, quetiapine, risperi-
done and ziprasidone, in a clinically relevant sample of
patients acutely admitted to a psychiatric hospital with
psychosis. The hospital is responsible for all the acute
admissions in the catchment area.
Methods
Study design
Methods have been described in more detail in a pre-
vious publication [24]. The Bergen Psychosis Project
(BPP) is a 24-month, prospective, rater-blind, pragmatic,
randomized, head-to-head comparison of the effective-
ness of olanzapine, quetiapine, risperidone and ziprasi-
done. All patients were recruited from the Division of
Psychiatry at Haukeland University Hospital with a
catchment population of about 400,000. The BPP was
approved by the Regional Committee for Medical
Research Ethics and the Norwegian Social Science Data
Services. Funding of the project was initiated by the
Research Council of Norway, followed by the Western
Norway Regional Health Authority and Haukeland Uni-
versity Hospital, Division of Psychiatry. The BPP did not
receive any financial or other support from the pharma-
ceutical industry.
Patients
The Regional Committee for Medical Research Ethics
allowed eligible patients to be included before informed
consent was provided, thus entailing a clinically relevant
representation in the study. Any investigation that was
beyond normal clinical practice was introduced only after
informed consent was obtained. Patients (age ≥ 18 years)
were eligible for the study if they were admitted to the
emergency ward for symptoms of psychosis as deter-
mined by a score of ≥ 4 on one or more of the following
items in the Positive and Negative Syndrome Scale
(PANSS): delusions, hallucinatory behavior, grandiosity,
suspiciousness/persecution or unusual thought content
[25] and were candidates for oral antipsychotic drug ther-
apy. The inclusion was based on the presence of psycho-
tic symptoms irrespective of diagnostic group, thus
reflecting the diagnostic uncertainty commonly present
in the early treatment phases in acutely admitted psycho-
tic patients who are nevertheless in need of antipsychotic
medication. Eligible patients met ICD-10 [26] diagnostic
criteria for schizophrenia, schizoaffective disorder, acute
and transient psychotic disorder, delusional disorder,
drug-induced psychosis, bipolar disorder except manic
psychosis and major depressive disorder with psychotic
features. The diagnoses were determined by the hospital’s
psychiatrists or specialists in clinical psychology. Patients
were excluded from the study if they: were unable to use
oral antipsychotics because depot formulations were indi-
cated, did not understand spoken Norwegian language,
were candidates for electroconvulsive therapy as deter-
mined by the attending psychiatrists, were suffering from
organic brain disorder - principally dementia or were
medicated with clozapine on admittance. Patients suffer-
ing from manic psychosis or who, due to other behavioral
or mental reasons, were unable to cooperate with the
assessments were also excluded from the study. Patients
with drug-induced psychoses were included only when
the condition did not resolve within a few days and when
antipsychotic drug therapy was indicated.
Treatments
The pragmatic design aspired to mimic the normal clini-
cal situation with regards to treatment allocation without
compromising the randomization which protects against
systematic differences between groups that are not
related to the treatment. Randomization to a sequence
was considered the preferred method. At admission, a
sealed and numbered envelope was opened by the
attending psychiatrist and then the patient was offered
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tiapine, risperidone or ziprasidone. The randomization
was open to the treating psychiatrist or physician and to
the patient. Both the treating clinician and/or the patient
could discard the SGA listed as number 1 on the list
because of medical contraindications to, or prior negative
experiences with the drug. In that case the next drug on
the list could be chosen. The same principle was followed
throughout the sequence. A reason for discarding a drug
was requested. In each sequence, the SGA listed as 1
defined the randomization group (RG). The actual SGA
chosen, regardless of randomization group, defined the
first-choice group (FCG). Further dosing, combination
with other drugs or switching to another antipsychotic
drug were then left at the clinician’s discretion. Apart
from sporadic use, the patients in the project could use
only one antipsychotic drug, except during the cross-
taper period associated with a change of antipsychotic
drug. This is in correspondence with leading treatment
guidelines which suggest combinations of antipsychotics
be used only as a last resort [27]. In cases where conco-
mitant use of more than one antipsychotic drug was
inevitable, the patient could not participate in the project.
Assessments
Assessments were performed at the following points of
time: at baseline, at 6 weeks from baseline or at discharge
if discharged before 6 weeks from baseline and at 3, 6, 12
and 24 months from baseline.
T h em a j o r i t yo fa s s e s s m e n t sw e r ep e r f o r m e db yo n e
trained investigator, EJ, assisted by HAJ and RAK. Train-
ing and inter-rater reliability testing were conducted with
a satisfactory inter-rater reliability. Before inclusion, eligi-
ble patients were interviewed by the investigator using
the Calgary Depression Scale for Schizophrenia (CDSS)
[28] and the PANSS. The CDSS has been specifically
developed to assess the level of depressive symptoms in
schizophrenia. Depression rating scales frequently used
in mood disorders may not sufficiently distinguish
depressive symptoms from positive, negative and extra-
pyramidal symptoms in psychosis. The CDSS consists of
9 items, each giving a score of 0 to 3 points. The total
CDSS sum score range is 0 to 27. A CDSS sum score > 6
has a specificity of 82% and a sensitivity of 85% for
predicting a major depressive episode [29]. We used a
c u t - o f fo f>6a n d≤ 6 in correspondence with the guide-
lines from the authors of the CDSS [29]. The PANSS
Depression Factor (PANSS-D) is the combined score of
items G1 (somatic concerns), G2 (anxiety), G3 (guilt feel-
ings), and G6 (depression) of the general psychopathol-
ogy part of the PANSS. Each item is scored from 1 to 7,
giving a total PANSS-D score ranging from 4 to 28.
Several previous articles have performed factor analyses
on the PANSS and described the PANSS-D as a measure
of depressive symptoms in psychotic patients [30-32]. In
the literature PANSS-D is also referred to as the Compo-
site PANSS Depression Factor, PANSS Anxio-Depressive
Dimension or PANSS Depression Subscale. Cognitive
functioning at baseline was assessed by means of the
Repeatable Battery for the Assessment of Neuropsycholo-
gical Status (RBANS) [33], shown to be highly sensitive
to the neurocognitive impairments associated with schi-
zophrenia [34,35]. Misuse or dependence was reported
according to Mueser et al [36].
At discharge from the hospital or at 6 weeks if not dis-
charged, the tests and examinations were repeated by a
rater who was unaware of the treatment. Serum level mea-
surements of the antipsychotics were conducted. Thus far,
all investigations and tests were part of the hospital’s rou-
tine for the management of patients suffering from psy-
chosis and became part of the patient’s medical record. At
this point, the patients were asked for informed consent to
be contacted and included in the follow-up project.
At follow-up visits 3, 6, 12 and 24 months after baseline,
measures of psychopathology were repeated by a rater
blind to treatment. At each visit, all medications were
recorded and the mean antipsychotic drug doses were cal-
culated. Antipsychotic drug doses for accepted sporadic
use of antipsychotics, other than the SGAs under investi-
gation, were converted to chlorpromazine equivalent
doses [37]. In cases where chlorpromazine equivalent
doses could not be found in the literature, this was done
by conversion to defined daily doses (DDDs) as developed
by the World Health Organization Collaborating Centre
for Drug Statistics Methodology [38]. The basic definition
of the DDD unit is the assumed average maintenance dose
per day for a drug used for its main indication in adults.
Statistical procedures
The primary analyses were intention-to-treat (ITT) ana-
lyses based on the randomization groups (RGs). That is,
trial participants were analyzed in the group to which they
were randomized regardless of which treatment they actu-
ally received, or how much treatment they received [39].
Secondary analyses were based on first choice groups
(FCGs). Baseline data were analyzed using SPSS software
(version 17.0) and by means of exact c
2 tests for categori-
cal data and one-way ANOVAs for continuous data. For
baseline comparisons between those lost to follow-up
before retesting and those who were retested, independent
samples T-tests were used for continuous data and exact
c
2 tests for categorical data.
Change of depressive symptoms was analyzed in R by
means of linear mixed effects (LME) models [40,41].
Fixed effects, i.e. systematic differences between the
drugs, were different linear slopes in the four treatment
groups, technically a group-by-time interaction with no
baseline group differences. The model calculates overall
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the variables in the follow-up period. This can be visually
represented by the slope of a linear curve with time on
the horizontal axis and the respective variable on the
vertical axis. Since the aim of the present study was to
investigate the overall change during the follow-up per-
iod, the LME model was considered to be the analysis of
choice for this purpose. The model uses all available data
and handles different numbers of visits, as well as differ-
ences in times between visits, by individual patients.
Furthermore, the mixed effects model has demonstrated
superior statistical power when the missing data is mod-
erately non-ignorable [42]. For multiple comparisons,
Benjamini-Hochberg adjustments were applied.
The CDSS and the PANSS are primarily developed to
assess patients with schizophrenia. As the sample is diag-
nostically heterogeneous, a Spearman correlation analysis
was performed using the SPSS software (version 17.0) to
determine the consistency across the CDSS and the
PANSS-D. The level of statistical significance was set at
a = 0.05, two-sided.
Power estimations were conducted in R by means of
LME models. The initial CDSS sum score and within-
person-variation were based on the results of a previous
model [24]. CDSS sum score reductions of 10%, 20%,
50% and 70% in the respective drug groups were consid-
ered to be clinically significant differences and the
corresponding slopes were entered into the model. For
comparison, the EUFEST study reported a 65% overall
reduction of the CDSS sum score at 12 months [15].
The initial CDSS sum score was set at 5.7 points in the
model and an estimated drop-out rate of 3% per month
was used. For each level of power 10,000 simulations
were run. Based on these premises for the power calcu-
lations, the trial should have 80% power to detect statis-
tically significant differences among the drugs with 45
subjects in each treatment group, and 90% power with
55 subjects in each group.
Results
The patient enrolment is displayed in Figure 1. Baseline
demographic and clinical characteristics are presented in
Additional file 1. A total of 226 patients were allocated to
randomized sequences of the first-line SGAs listed from
1 to 4. The SGAs listed as 1 defined the randomization
groups (RGs). A total of 185 (81.9%) patients received the
SGA listed as 1, whereas 40 (17.7%) received another
SGA on the list. The choice of SGA was unknown for
one patient. There were no differences among RGs in the
fractions of patients that did not choose the SGA listed
as 1. The sample represented a diverse population suffer-
ing from psychosis. Five patients were diagnosed with
co-morbid major depressive disorder in addition to a
primary psychotic disorder; two were in the risperidone
group and one in each of the other groups.
Primary outcomes - ITT analyses based on RGs
There were no statistically significant differences in base-
line demographic and clinical characteristics between the
RGs, thus confirming a successful randomization. There
was no difference among the groups with regards to time
until discontinuation of allocated drug. There were gener-
ally no substantial differences on baseline clinical or
demographic characteristics between those who were lost
to follow-up before retesting and those who were retested,
with the exception of a slightly higher PANSS negative
sub-score for those lost to follow-up (20.8 vs. 18.5 points
(independent samples T-Test: p = 0.02; mean difference
2.3 points; 95% confidence interval (CI) 0.4-4.2)). The
mean CDSS sum score at baseline was 6.4 points, varying
between 0 to 23 points. The mean baseline PANSS-D sum
score was 10.8 points, varying between 4 to 22 points.
A total of 96 (42.7%) of the patients had a CDSS sum
score > 6 points. The CDSS sum score and PANSS-D
score correlated significantly (Spearman correlation coeffi-
cient r = 0.77; p < 0.01) (Figure 2). The symptom out-
comes quantified by the CDSS and the PANSS-D are
presented in Table 1. There was a significant time-effect
showing a steady decline in depressive symptoms in all
medication groups (Figures 3 and 4). Pair-wise compari-
sons demonstrated no statistically significant differences
b e t w e e nt h eR G so nt h ep r i m ary outcomes. Analyses
restricted to the first 90 days revealed no substantial differ-
ences among the SGAs. When affective psychoses and
substance-induced psychoses, respectively, were excluded
in sensitivity analyses for the whole follow-up, essentially
the same results were revealed. In separate analyses in the
groups with CDSS sum score > 6 or ≤ 6, respectively,
there were no statistically significant differences between
the SGAs. In sub-analyses on single CDSS items there
were no statistically significant differences among the
SGAs, except for item 8 (suicidality), as the risperidone
group had a steeper daily reduction of the score compared
to the olanzapine group (LME: p = 0.031). Corrected for
multiple comparisons, this difference was no longer statis-
tically significant (LME: p = 0.187). There were no statisti-
cally significant differences among the SGAs concerning
anti-depressive effectiveness on the PANSS item G6
(depression).
Secondary outcomes based on FCGs
There were generally no substantial differences among
FCGs on baseline demographic and clinical characteristics,
with the exception of a slightly higher PANSS positive
sub-score for olanzapine (21.6 points) compared with ris-
peridone (18.4 points) (one-way ANOVA: p < 0.001; mean
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Page 4 of 10difference 3.2 points; 95% CI 1.1-5.3) and ziprasidone (19.2
points) (one-way ANOVA: p = 0.011; mean difference
2.5 points; 95% CI 0.4-4.5). The mean doses in milligrams
per day with standard deviations (SD) were 14.5 (5.0) for
olanzapine-, 339.3 (193.4) for quetiapine-, 3.3 (1.1) for
risperidone- and 100.3 (42.2) for ziprasidone-treated
groups. The mean serum levels in nanomoles per liter
with SD were 100.4 (72.4) for olanzapine, 398.2 (510.2) for
quetiapine, 81.4 (58.3) for risperidone and 122.9 (91.3) for
ziprasidone. The reference ranges were 30-200, 100-800,
30-120, and 30-200 for olanzapine, quetiapine, risperidone
and ziprasidone, respectively. Data concerning psychotro-
pic treatment was analyzed for the 108 patients who were
available for retesting at discharge or at 6 weeks. A total of
30 (26.5%) patients changed their first-chosen SGA during
follow-up. There were no differences among the FCGs in
the frequency of change or choice of new antipsychotic
drug. One or more doses of low-potency first-generation
antipsychotics were given to 16 patients (14.8%). There
were no differences among the FCGs in the number of
patients receiving additional antipsychotics or the mean
daily additional antipsychotic dose in chlorpromazine
equivalents. 80 (74.1%), 28 (25.9%) and 7 (6.5%) patients
received additional benzodiazepines, antidepressants and
mood stabilizers, respectively. In 35 (32.4%) of these
patients 2 or more of the additional psychotropics were
used in combination. There were no differences among
FCGs in the use of these additional psychotropics. Antic-
holinergics were prescribed for 6 (23.1%) of risperidone-
treated FCGs. The corresponding figures were 1 (3.4%) for
olanzapine-, 0 for quetiapine- and 5 (18.5%) for ziprasi-
done-treated FCGs (exact c
2 test: p = 0.009). There were
Randomized 
(N=226) (30.5%) 
Assessed for eligibility 
(100%)
1 
Excluded 
Not meeting inclusion criteria (1.2%)
1 
Unable to assess  
(uncoop, organic braindis.) (46.5%)
1 
Randomization not acceptable (6.8%)
1 
Administrative causes (15.0%)
1 
Risperidone 
Allocated to drug (N=57) 
Received allocated drug (N=44) 
Chose another drug (N=12) 
Unknown choice of drug (N=1) 
Did not take any drug doses of 
received allocated drug (N=5) 
Lost to follow-up
2 
Uncoop (N=13) 
Polypharmacy (N=4) 
Discharge (N=8) 
Depot (N=0) 
Other (N=1) 
Total (N=26) 
Follow-up 
Discharge/ 6 weeks (N=30)
3 
3 months (N=15) 
6 months (N=10) 
12 months (N=11) 
24 months (N=3) 
Lost to follow-up
2 
Uncoop (N=7) 
Polypharmacy (N=6) 
Discharge (N=15) 
Depot (N=1) 
Other (N=1) 
Total (N=30) 
Lost to follow-up
2 
Uncoop (N=6) 
Polypharmacy (N=1) 
Discharge (N=17) 
Depot (N=0) 
Other (N=1) 
Total (N=25) 
Follow-up 
Discharge/ 6 weeks (N=23)
3 
3 months (N=14) 
6 months (N=11) 
12 months (N=9) 
24 months (N=6) 
Follow-up 
Discharge/ 6 weeks (N=27) 
3 months (N=11) 
6 months (N=8) 
12 months (N=6) 
24 months (N=5) 
Follow-up 
Discharge/ 6 weeks (N=29)  
3 months (N=12) 
6 months (N=9) 
12 months (N=7) 
24 months (N=1) 
Analyzed (N=57)  Analyzed (N=54)  Analyzed (N=52)  Analyzed (N=63) 
Lost to follow-up
2 
Uncoop (N=7) 
Polypharmacy (N=6) 
Discharge (N=12) 
Depot (N=1) 
Other (N=8) 
Total (N=34) 
Olanzapine 
Allocated to drug (N=54)  
Received allocated drug (N=45) 
Chose another drug (N=9) 
Did not take any drug doses of 
received allocated drug (N=5)  
 
Quetiapine 
Allocated to drug (N=52) 
Received allocated drug (44) 
Chose another drug (N=8) 
Did not take any drug doses of 
received allocated drug (N=3) 
 
Ziprasidone 
Allocated to drug (N=63) 
Received allocated drug (=52) 
Chose another drug (N=11) 
Did not take any drug doses of 
received allocated drug (N=4) 
 
Figure 1 Flow of patients through the study. Not meeting inclusion criteria = score below 4 on all the items: delusions, hallucinatory
behaviour, grandiosity, suspiciousness/persecution or unusual thought content in the Positive and Negative Syndrome Scale (PANSS); Uncoop. =
the patient was not able or willing to cooperate with testing and assessments; Organic braindis. = Organic brain disorder, principally dementia;
Randomization not acceptable = patient or treating clinician not willing to change existing antipsychotic medication; Administrative causes =
principally patient discharged before assessments could be made.
1 Enrolment started March 2003 until 2008, week 26. Full details on enrolment
were only registered from 2006, week 31 until 2008, week 26. Consequently only percentages are displayed for patients assessed for eligibility
and excluded patients.
2 Before discharge/6 weeks.
3 One patient in the risperidone and olanzapine groups missed the first follow-up visit, but
was retested on later visits.
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chotic drug use the year prior to index hospitalization.
The PANSS-D and CDSS scores of the primary ana-
lyses were essentially unaltered in the secondary analyses.
This also applied to the sensitivity analysis restricted to
the first 90 days, and to the period of actual intake of the
first chosen antipsychotic drug.
Discussion
The primary aim of the present study was to investigate
whether differential anti-depressive effectiveness is present
among olanzapine, quetiapine, risperidone and ziprasidone
in a clinically relevant sample of patients acutely admitted
to hospital for symptoms of psychosis. The study was
funded independently of the pharmaceutical industry and
the patients were followed for up to 2 years during every-
day clinical circumstances. This strengthens the applicabil-
ity of the results to acutely admitted patients with
psychosis in general.
There were no substantial differences among the SGAs
on the primary outcome measure. The results are in line
with those of the recently published EUFEST and CATIE
effectiveness studies that included schizophrenia patients
in first episode and chronic phase, respectively [15,16].
The collected evidence from naturalistic studies in
psychosis thus indicates that if differential anti-depressive
effectiveness exists among the drugs, this is likely to be of
only marginal magnitude in clinical practice. As the sam-
ple was diagnostically heterogeneous the primary out-
come was measured by two different inventories: the
PANSS-D and the CDSS. The correlation between the
sum scores of the inventories was good, but left substan-
tial variance unexplained, thus underlining the rationale
Figure 2 Correlation between CDSS sum score and PANSS-D-
score at baseline. CDSS = the Calgary Depression Scale for
Schizophrenia; PANSS = the Positive and Negative Syndrome Scale;
PANSS-D score = PANSS Depression factor = sum score of items
G1-G3 and G6 in the general psychopathology subscale of the
PANSS.
Table 1 Numerical results of the CDSS and the PANSS-D
Outcome Measures - Change/Day Risperidone
(N = 57)
Olanzapine
(N = 54)
Quetiapine
(N = 52)
Ziprasidone
(N = 63)
CDSS item 1
Depression
-0.0016 -0.0011 -0.0017 -0.0022
CDSS item 2
Hopelessness
-0.0010 -0.0002 -0.0005 -0.0008
CDSS item 3
Self depreciation
0.0083 -0.0002 -0.0005 -0.0006
CDSS item 4
Guilty ideas of reference
-0.0005 -0.0007 -0.0006 -0.0011
CDSS item 5
Pathological guilt
-0.0010 -0.0052 -0.0004 -0.0011
CDSS item 6
Morning depression
-0.0011 -0.0006 -0.0005 -0.0009
CDSS item 7
Early awakening
-0.0009 -0.0002 -0.0003 -0.0003
CDSS item 8
Suicide
-0.0011 -0.0002 -0.0004 -0.0006
CDSS item 9
Observed depression
-0.0008 -0.0001 -0.0004 -0.0006
CDSS sum score -0.0093 -0.0033 -0.0048 -0.0080
PANSS item G6:
Depression
-0.0015 -0.0020 -0.0027 -0.0023
PANSS-D score -0.0014 -0.0012 -0.0014 -0.0018
N = Number of Patients; Change/Day = Mean Change of Outcome Measure per Day; CDSS = The Calgary Depression Scale for Schizophrenia. PANSS = The
Positive And Negative Syndrome Scale for Schizophrenia. PANSS-D = The sum score of items G1-G3 + G6 of the General Psychopathology subscale of the PANSS.
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majority of prior studies indicating anti-depressive differ-
ences among antipsychotics are short term [17,19,21,43].
If the anti-depressive effects of the drugs occur mainly
within the first weeks to months of treatment, differential
effectiveness may, in theory, be blurred in a longer time
frame. Based on the sensitivity analyses restricted to the
first 90 days of follow-up our data do not support this
hypothesis. Consistent with our findings there was a sig-
nificant overall decrease of the CDSS score in the CATIE
study. Neither study had a placebo arm, which makes
interpretation of this result difficult with regards to asses-
sing the anti-depressive effectiveness of the drugs.
Depression is highly prevalent in first-episode and
acute phase psychosis [44,45]. The mean CDSS sum
score in the BPP at baseline was 6.5. The CDSS sum
score was > 6 for 42.7% of the sample. DeNayer et al.
[ 2 1 ] ,u s i n gt h es a m eC D S S - s c o r ec u t - o f fa si no u rs t u d y ,
found significant reductions both in the groups with
CDSS sum scores > 6 and ≤6p o i n t s ,r e s p e c t i v e l y .O u r
analyses demonstrated no statistically significant differ-
ences among the SGAs in either group based on this sub-
division. The equal anti-depressive effectiveness found
also in the group with CDSS sum score > 6, supports our
main findings. Caution should be given to the fact that
subgroup analyses increase the risk of statistical type II
errors. In the CATIE study quetiapine was found to be
superior to risperidone in patients with a CDSS score ≥6
[16]. However, the more depressed group became rela-
tively larger in the CATIE-trial as a consequence of the
lower cut-off (CDSS ≥ 6) for depression.
The sample was diagnostically heterogeneous, though
with equal diagnostic distribution among the RGs.
Hypothetically, different diagnostic groups could differ
in anti-depressive susceptibility from the SGAs, which
could blur the overall picture. We therefore conducted
sensitivity analyses, excluding the affective psychoses
and substance-induced psychoses which did not skew
the results. The proportion of primary affective disor-
ders was rather low.
Some limitations apply to the study. In a moderately
sized clinical trial like the Bergen Psychosis Project, the
possibility of a type II statistical error exists. The BPP has,
however, proven statistically powerful enough to disclose
differences among the SGAs on several outcomes [24].
Furthermore, power analyses indicate that the study
should have a sufficient number of subjects to detect clini-
cally significant differences in anti-depressive effectiveness
among the drugs, if present. The pragmatic design was
chosen to address issues relevant to everyday clinical prac-
tice. The resulting heterogeneous sample does not have
enough power to conclude statistically inside particular
diagnostic subgroups. The randomization procedure
allowing the patient or clinician to choose a different drug
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Figure 3 Change of CDSS sum score. Linear mixed effects model
curves. Linear slopes for the randomization groups generated based
on linear mixed effects models, CDSS sum score output, as displayed
in Table 1 for olanzapine, quetiapine, risperidone and ziprasidone,
respectively. The curves are confined to the first 300 days because the
major bulk of data is obtained before 300 days. CDSS = the Calgary
Depression Scale for Schizophrenia.
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Figure 4 Change of PANSS-D score. Linear mixed effects model
curves. Linear slopes for the randomization groups generated based
on linear mixed effects models, PANSS-D score output, as displayed
in Table 1 for olanzapine, quetiapine, risperidone and ziprasidone,
respectively. The curves are confined to the first 300 days because
the major bulk of data is obtained before 300 days. PANSS = The
Positive and Negative Syndrome Scale; PANSS-D = PANSS
Depression Factor = sum score of items G1-G3 and G6 in the
general psychopathology subscale of the PANSS.
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Page 7 of 10than the first one could potentially introduce bias if there
were differences among the groups in the proportions
accepting the first SGA on the list. No such differences
were unveiled. Furthermore,t h ep r i m a r ya n a l y s e sw e r e
intention to treat analyses based on the randomization
groups. It could be argued given the naturalistic design of
the study, with assessments not restricted to the time
frame of actual use of the first SGA, that the outcomes
may not be related to that particular SGA, but to subse-
quent medications. We have, however, demonstrated that
about three-quarters of the patients did not change their
original SGA. Moreover, there were no differences among
groups in the rate of antipsychotic medication changes or
the choice of a new antipsychotic agent for those who did
change. Furthermore, time until discontinuation was gen-
erally the same for all SGAs. Finally, the analyses restricted
to the period of actual use of first chosen drug revealed
generally the same results as the primary analyses. Inher-
ent to the pragmatic design which permits the use of con-
comitant psychotropics, the net effects of the SGAs under
investigation may be somewhat blurred by effects of the
concomitant psychotropics. The randomization was open
to the patient and the treating clinician in order to imitate
a clinically realistic setting. This could have introduced
bias if some of the SGAs were more popular among the
clinicians or patients. There was a high attrition rate,
although not significantly different between the randomi-
zation groups. To our best knowledge this is a major pro-
blem in all clinical antipsychotic drug trials. Leucht and
collaborators [46] state in their methodology paper that
even in short-term trials of only 4 to 10 weeks more than
40% of participants discontinue prematurely. Given the
long follow-up of our study we expected a high drop-out
rate. This was the main reason for the choice of the
mixed-effects statistical method applied, as this method is
one of the preferred ones in such a situation. Reasons for
drop-out were not recorded and the possibility that the
more depressed patients dropped out cannot be ruled out.
Still, comparisons on baseline characteristics between
those with long term follow-ups and the ones leaving the
study early, do not point to substantial clinical differences
among the groups. Of those assessed for eligibility, only
30% were included in the trial. Theoretically, including
only a fraction of eligible participants could limit the
applicability of the results to the whole population. On the
other hand, other clinical trials studying antipsychotics
included only between 7-14% [47]. The diagnoses were
determined by psychiatrists or specialists in clinical psy-
chology, and structured clinical interviews were not sys-
tematically used, which may decrease the validity and
reliability of the diagnoses. The ITT-analyses may lead to
an underestimation of treatment effect. However, the sub-
stantially equal results of the ITT- and FCG-analyses indi-
cate that this was not the case in this trial. Analyses
involving single items in the CDSS should be interpreted
with caution as the data are unlikely to be normally dis-
tributed. Finally, the CDSS-instrument is designed to mea-
sure depressive symptoms in schizophrenia specifically.
Our sample was diagnostically heterogeneous. Somewhat
surprisingly, considering that few trials indicate a superior
antipsychotic effectiveness of quetiapine [15,48,49], the
recently published results of the Bergen Psychosis Project
demonstrated a significant superiority of quetiapine com-
pared with olanzapine and risperidone on several psycho-
metric scales. The present study shows that the superiority
of quetiapine could not be explained by a stronger anti-
depressive effect.
Conclusions
In conclusion, the results of this study demonstrate no
substantial differences in anti-depressive effectiveness
between olanzapine, quetiapine, risperidone and ziprasi-
done in a clinically relevant sample of psychotic patients
with moderate depressive symptoms. Based on our find-
ings we can make no recommendations concerning
choice of any particular SGA for targeting symptoms of
depression in a patient acutely admitted with psychosis.
Additional material
Additional file 1: Demographic and clinical characteristics at
baseline. This table displays baseline comparisons of demographic
characteristics, clinical characteristics (drug- and alcohol-use, diagnoses,
antipsychotic-naïve) and baseline psychometric results between the
randomization groups.
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